From Nerve to Brain: Toward a Mechanistic Understanding of Spinal Cord Stimulation in Human Subjects
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Estimated)
Enrollment
Phase
Phase
- Phase 2
Contacts and Locations
Study Contact
Study Contact
- Name: Brian Wainger, MD PhD
- Phone Number: 617-726-8810
- Email: BWAINGER@PARTNERS.ORG
Study Locations
-
-
Massachusetts
-
Boston, Massachusetts, United States, 02114
- Recruiting
- Massachusetts General Hospital
-
Contact:
- Brian Wainger, MD PhD
-
Sub-Investigator:
- Marco Loggia, PhD
-
Boston, Massachusetts, United States, 02215
- Recruiting
- Beth Israel Deaconess Medical Center
-
Contact:
- Roy Freeman, MD
-
Boston, Massachusetts, United States, 02215
- Recruiting
- Brigham and Women's Hospital
-
Contact:
- Christopher Gilligan, MD
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Aged 18 to 80
- Capable of providing informed consent and following trial procedures, including capacity to complete self-reported measures of pain, function, and other outcomes
- Stably implanted spinal cord or dorsal root ganglion stimulator
- Device is to treat back/radicular lower extremity pain or neck/arm pain
- Device with a paresthesia-free setting
Exclusion Criteria:
- Patients who are not on a stable dose of opioids or are on a stable dose greater than 100 MME/day per day within the two months prior to enrollment, or those who are unwilling to maintain a stable dose of opioids throughout the duration of the study
- The investigator concludes that the participant is unable to differentiate back or neck/arm pain from other pains
- Systemic or psychiatric illness that in the opinion of the site investigator would interfere with the individual's ability to participate in the trial
- Other factor that in the opinion of the site investigator would interfere with the individual's ability to participate in the trial or tolerate the study procedures
Dropout Criteria for Optional Imaging
- Stimulation device is not 3 Tesla magnetic resonance imaging compliant
- Contraindications to magnetic resonance imaging and/or positron emission tomography scanning (including presence of a cardiac pacemaker or pacemaker wires, vascular clips in the head or previous neurosurgery, prosthetic heart valves, claustrophobia)
- Pregnant or breastfeeding
- Participants with a low affinity binder phenotype based off testing for the Ala147Thr polymorphism.
- Current or recent use of benzodiazepines (except for alprazolam, clonazepam, and lorazepam). Recent use will be defined based off the benzodiazepines half-life, such that patients who stopped taking the medication at least five half-lives ago will be considered eligible for scanning.
- Subjects who have exceeded (or would exceed if they were to participate) the yearly amount of allowable radiation, as defined by the Radiation Safety Committee
- In the opinion of the investigators, unable to safely participate in this study and/or provide reliable data (e.g., unlikely to remain still during the imaging procedures).
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Other
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: Quadruple
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Other: Patients with Implanted Devices on Minimal/No Stimulation Settings
Patients in this arm will be randomized to turn off their spinal cord stimulator (or to minimal settings).
|
Patients in this intervention group will have their spinal cord stimulator turned off or to the minimal settings possible.
Patients with imaging compatible devices will undergo positron emission tomography/magnetic resonance imaging at three time points during the study.
This imaging involves administration of the [11C]PBR28 radioligand, which is an investigational drug.
Only a subset of patients who have 3 Tesla magnetic resonance imaging compatible stimulators will undergo this imaging.
|
|
Other: Patients with Implanted Devices on Usual Stimulation Settings
Patients in this arm will be randomized to turn on their spinal cord stimulator to their usual stimulation settings.
|
Patients in this intervention group will have their spinal cord stimulator turned on to their usual stimulation settings.
Patients with imaging compatible devices will undergo positron emission tomography/magnetic resonance imaging at three time points during the study.
This imaging involves administration of the [11C]PBR28 radioligand, which is an investigational drug.
Only a subset of patients who have 3 Tesla magnetic resonance imaging compatible stimulators will undergo this imaging.
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Supraexcitability
Time Frame: From baseline (enrollment) to six weeks
|
The primary outcome will be superexcitability (indicating paired pulse facilitation) measured by threshold tracking nerve conduction.
|
From baseline (enrollment) to six weeks
|
Collaborators and Investigators
Sponsor
Sponsor
Collaborators
Collaborators
Investigators
Investigators
- Principal Investigator: Brian Wainger, MD PhD, Massachusetts General Hospital
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Estimated)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- 2022P001803
- 1RM1NS128741-01 (U.S. NIH Grant/Contract)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.